Plasmalogens, phospholipases A2 and signal transduction

Area of Science:

• Neuroscience
• Biochemistry
• Enzymology

Background:

• Plasmalogen breakdown in neural membranes is implicated in neurodegenerative diseases.
• Evidence suggests a specific enzyme, plasmalogen-selective phospholipase A2, catalyzes this process.

Purpose of the Study:

• To characterize the newly purified plasmalogen-selective phospholipase A2 from bovine brain.
• To differentiate this enzyme from other known phospholipase A2 isoforms.
• To explore its potential role in neurological disorders and as a therapeutic target.

Main Methods:

• Purification of plasmalogen-selective phospholipase A2 from bovine brain.
• Enzyme activity assays with varying substrates and inhibitors.
• Analysis of cofactor requirements (e.g., Ca2+) and molecular mass determination.
• Investigation of inhibition patterns by glycosaminoglycans, gangliosides, and sialoglycoproteins.

Main Results:

• The enzyme is a 39 kDa cytosolic protein, independent of Ca2+.
• It exhibits strong inhibition by glycosaminoglycans (heparan sulfate > hyaluronic acid > chondroitin sulfate > heparin).
• Gangliosides and sialoglycoproteins also inhibit the enzyme.
• Its properties distinguish it from the 85 kDa Ca(2+)-dependent cytosolic phospholipase A2.

Conclusions:

• A distinct plasmalogen-selective phospholipase A2 has been identified and characterized.
• This enzyme may be regulated by glycosaminoglycans and sialoglycoconjugates.
• It is potentially involved in K+ channel regulation and fatty acid release during ischemic injury, representing a promising therapeutic target for neurodegenerative diseases.